30 results
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
and together, may affect Landos’ long-term strategic goals and plans. As part of this process, members of Landos senior management have engaged from time … or in part based on achievement of performance goals or metrics.
“Company Preferred Stock” means the preferred stock, $0.01 par value per share
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
and financial markets generally, as they, individually and together, may affect Landos’ long-term strategic goals and plans. As part of this process … by the Company) whose vesting is conditioned in full or in part based on achievement of performance goals or metrics.
“Company Preferred Stock” means
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
9:19am
, or otherwise issued or granted by the Company) whose vesting is conditioned in full or in part based on achievement of performance goals or metrics.
“Company
8-K
EX-2.1
LABP
Landos Biopharma Inc
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
by the Company) whose vesting is conditioned in full or in part based on achievement of performance goals or metrics.
“Company Preferred Stock” means
8-K
EX-99.1
kx104k
4 Jan 24
Regulation FD Disclosure
8:05am
8-K
EX-99.2
97lrfb01t ds
12 May 23
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
8:40am
PRE 14A
dc859ej iodszv9
10 Apr 23
Preliminary proxy
4:20pm
8-K
jl1w3yr2meaz3xam3h
21 Jun 22
Departure of Directors or Certain Officers
4:20pm
8-K
EX-99.1
abyeegcs
12 May 22
Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update
4:21pm
DEF 14A
eu197fonr6 nb4n8a
28 Apr 22
Definitive proxy
4:16pm
S-8
EX-99.3
1yshm6tgcxws78xlz5m1
24 Mar 22
Registration of securities for employees
5:21pm
8-K
y58yxtf
21 Dec 21
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
7o7jye1g6qrbo u8
3 Nov 21
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis
8:00am
10-K
fpd4ran5sf0
31 Mar 21
Annual report
5:03pm
424B4
jpasf2etcok fs0dr
4 Feb 21
Prospectus supplement with pricing info
5:02pm